OSMI-1 NEW
| Price | $34 | $48 | $77 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: OSMI-1 | CAS No.: 1681056-61-0 |
| Purity: 99.83% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | OSMI-1 |
| Description | OSMI-1 is an O-GlcNAc transferase (OGT) inhibitor (IC50=2.7 μM) that is orally active and cell-permeable. OSMI-1 inhibits protein O-GlcNA acetylation without qualitatively altering cell-surface N- or O- linked glycans. |
| In vitro | METHODS: COS7 and Hela cells were treated with OSMI-1 (2-100 μM) for 24 h. Cell viability was measured using the CCK8 Assay. RESULTS: 50 μM OSMI-1 reduced cell viability by more than 50%. [1] METHODS: CHO cells were treated with OSMI-1 (10-100 μM) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: OSMI-1 reduced global OGlcNAcylation in a dose-dependent manner, with a maximum effect at 50 μM. [2] |
| In vivo | METHODS: To assay antitumor activity in vivo, OSMI-1 (1 mg/kg, i.v.) and TRAIL (500 μg/kg, intraperitoneally) were administered to BALB/c-Foxn1nu/ArcGem nude mice harboring human colorectal carcinoma tumor HCT116 once daily for three weeks. RESULTS: Tumor size was slightly reduced in mice treated with OSMI-1 or TRAIL alone, but significantly reduced in the OSMI-1 and TRAIL combination group. The combination treatment synergistically increased the antitumor activity of transplanted tumors in HCT116 nude mice. [3] METHODS: To investigate the protective effect against Stx-mediated pathogenic responses, OSMI-1 (300-1000 μg/mouse in water containing 4.5% DMSO and 5% Tween 80) was injected intraperitoneally into Stx2a-attacked C57BL/6 mice once daily for seven days. RESULTS: O-GlcNAc inhibition ameliorated the mortality and various disease symptoms induced by Stx2a exposure in mice, which was further enhanced by O-GlcNAc inhibition. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 18.33 mg/mL (32.53 mM), Sonication is recommended. |
| Keywords | cell-permeable | Inhibitor | OGT | Diacylglycerol acyltransferase | O-GlcNAcylation | toxicity | mammalian | inhibit | Acyltransferase | OSMI-1 | zebrafish | OSMI1 | OSMI 1 | acyl-CoA:cholesterol acyltransferase | Diglyceride acyltransferase | O-GlcNAc | mono- acylglycerol acyltransferase | transferase |
| Inhibitors Related | Xanthohumol | Lecimibide | Avasimibe | Cyclandelate | Eldacimibe | YM17E | 2-Furoic acid | Eflucimibe | Monatepil 2maleate | A 922500 | TMP-153 | PF-04620110 |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3400.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-05 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY